Antitumor effect of interleukin-2 against renal cell carcinoma

M. Oya; K. Marumo; H. Tazaki

doi:10.4993/acrt1992.2.129

Antitumor effect of interleukin-2 against renal cell carcinoma

M. Oya, K. Marumo, H. Tazaki

Department of Urology

Research output: Contribution to journal › Article › peer-review

Abstract

Renal cell carcinoma (RCC) is one of the most insensitive urologic tumors to either radiotherapy or anticancer chemotherapy. Several reports have shown that interferon (IFN) is the agent of great promise to treat advanced RCC. However, the effectiveness of IFN is limited.¹⁾ Eighteen patients with advanced RCC were treated by IL2. Antitumor effects were evaluated according to immunological parameters and survival rates.

Original language	English
Pages (from-to)	129-130
Number of pages	2
Journal	Annals of Cancer Research and Therapy
Volume	2
Issue number	1
DOIs	https://doi.org/10.4993/acrt1992.2.129
Publication status	Published - 1993

Keywords

Interleukin-2
Renal cell carcinoma

ASJC Scopus subject areas

Oncology
Cancer Research
Pharmacology (medical)

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.4993/acrt1992.2.129

Cite this

@article{87d159cae0c54f418f280a427f1aa57d,

title = "Antitumor effect of interleukin-2 against renal cell carcinoma",

abstract = "Renal cell carcinoma (RCC) is one of the most insensitive urologic tumors to either radiotherapy or anticancer chemotherapy. Several reports have shown that interferon (IFN) is the agent of great promise to treat advanced RCC. However, the effectiveness of IFN is limited.1) Eighteen patients with advanced RCC were treated by IL2. Antitumor effects were evaluated according to immunological parameters and survival rates.",

keywords = "Interleukin-2, Renal cell carcinoma",

author = "M. Oya and K. Marumo and H. Tazaki",

year = "1993",

doi = "10.4993/acrt1992.2.129",

language = "English",

volume = "2",

pages = "129--130",

journal = "Annals of Cancer Research and Therapy",

issn = "1344-6835",

publisher = "PJD Publications Ltd",

number = "1",

}

TY - JOUR

T1 - Antitumor effect of interleukin-2 against renal cell carcinoma

AU - Oya, M.

AU - Marumo, K.

AU - Tazaki, H.

PY - 1993

Y1 - 1993

N2 - Renal cell carcinoma (RCC) is one of the most insensitive urologic tumors to either radiotherapy or anticancer chemotherapy. Several reports have shown that interferon (IFN) is the agent of great promise to treat advanced RCC. However, the effectiveness of IFN is limited.1) Eighteen patients with advanced RCC were treated by IL2. Antitumor effects were evaluated according to immunological parameters and survival rates.

AB - Renal cell carcinoma (RCC) is one of the most insensitive urologic tumors to either radiotherapy or anticancer chemotherapy. Several reports have shown that interferon (IFN) is the agent of great promise to treat advanced RCC. However, the effectiveness of IFN is limited.1) Eighteen patients with advanced RCC were treated by IL2. Antitumor effects were evaluated according to immunological parameters and survival rates.

KW - Interleukin-2

KW - Renal cell carcinoma

UR - http://www.scopus.com/inward/record.url?scp=85024447059&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85024447059&partnerID=8YFLogxK

U2 - 10.4993/acrt1992.2.129

DO - 10.4993/acrt1992.2.129

M3 - Article

AN - SCOPUS:85024447059

SN - 1344-6835

VL - 2

SP - 129

EP - 130

JO - Annals of Cancer Research and Therapy

JF - Annals of Cancer Research and Therapy

IS - 1

ER -

Antitumor effect of interleukin-2 against renal cell carcinoma

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this